Karius is a life sciences company focused on conquering infectious diseases through the innovative use of next-generation sequencing to analyze microbial cell-free DNA. The company's genomics platform delivers unprecedented insight into the microbial landscape, providing clinicians with a comprehensive test capable of identifying more than a thousand pathogens directly from blood and helping industry accelerate drug development.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/07/17 | $50,000,000 | Series A |
Innovation Endeavors Khosla Ventures Spectrum 28 Tencent Holdings  | undisclosed |
| 02/24/20 | $165,000,000 | Series B |
HBM Healthcare Investments Khosla Ventures SoftBank Vision Fund 2 | undisclosed |
